Non-Brain Penetrant CB1 Antagonists From Jenrin Discovery Show Beneficial Effects In Treating Diabetes And Obesity

Research shows that proprietary non-brain penetrant cannabinoid subtype 1 (CB1) receptor antagonists developed by Jenrin Discovery are able to produce metabolically favorable effects in peripheral tissues, including fat and liver.

More: continued here

Filed under: Diabetes on November 2nd, 2008